Utah Medical Products
UTMD

$69.48

1.39%

Market Cap: 245M

About: Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals as well as outpatient clinics and physicians offices.

Employees: 190

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

15% more funds holding

Funds holding: 88 [Q4 2023] → 101 (+13) [Q1 2024]

13% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 32

0.08% more ownership

Funds ownership: 69.28% [Q4 2023] → 69.36% (+0.08%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

16% less capital invested

Capital invested by funds: $212M [Q4 2023] → $177M (-$34.8M) [Q1 2024]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for UTMD.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales

Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.

Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024

SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024

Zacks Investment Research

Zacks Initiates Coverage of UTMD With Neutral Recommendation

Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry.

Zacks Initiates Coverage of UTMD With Neutral Recommendation

Utah Medical Products, Inc. Announces Quarterly Dividend

SALT LAKE CITY, UT / ACCESSWIRE / May 7, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on July 5, 2024 to stockholders of record at the close of business on June 14, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.

Utah Medical Products, Inc. Announces Quarterly Dividend

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024

SALT LAKE CITY, UT / ACCESSWIRE / April 25, 2024 / In the first calendar quarter (1Q) of 2024, Utah Medical Products, Inc. (NASDAQ:UTMD) attained financial results consistent with its previously announced projections for calendar year 2024. Summary of results.

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024

The Motley Fool

2 Beaten-Down Stocks That Could Be Ready to Soar

These beaten-down stocks have lots of long-term potential.

2 Beaten-Down Stocks That Could Be Ready to Soar

Utah Medical Products, Inc. Announces Quarterly Dividend

SALT LAKE CITY, UT / ACCESSWIRE / February 6, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on April 3, 2024 to stockholders of record at the close of business on March 15, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.

Utah Medical Products, Inc. Announces Quarterly Dividend

UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance

SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial results for the full year of 2023 consistent with management's beginning of year projections.

UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance

See News Rankings